Freston J W, Triadafilopoulos G
University of Connecticut Health Center, Farmington Avenue, Farmington, CT 06030-1111, USA.
Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:35-42. doi: 10.1111/j.0953-0673.2004.01837.x.
The goals of gastro-oesophageal reflux disease (GERD) treatment are to control symptoms, heal the injured oesophageal mucosa, and prevent complications. Pharmacological therapy is effective in producing acute symptom relief and mucosal healing, as well as the long-term maintenance of remission. Proton pump inhibitors are the mainstay of GERD therapy. However, the need for daily administration, failure to provide complete symptom relief and costs of these agents may limit their use in some patients, prompting a consideration of alternative treatment strategies. Laparoscopic fundoplication may achieve symptom relief and healing of the oesophagitis in these individuals, but its invasiveness, cost and inherent surgical risks have created an interest in endoscopic therapies for GERD, with several emerging during the past few years. These interventions may either be viewed as an alternative therapy or as 'bridge' therapy, with patients still choosing to be treated with acid anti-secretory drugs or fundoplication if the endoscopic procedure fails to provide adequate symptom relief or if symptoms recur. Patient selection is critical for the success of fundoplication as well as endoscopic procedures, with ideal candidates being those with well-established endoscopically documented GERD, abnormal pH monitoring, normal oesophageal motility studies, and who have experienced at least partial symptom relief with proton pump inhibitor therapy. Hiatal hernia is not a contra-indication to fundoplication, while endoscopic intervention is best suited for those with a hiatal hernia of less than 3 cm in length. The long-term efficacy, cost-effectiveness, and impact of endoscopic procedures on extra-oesophageal manifestations of GERD and risk for GERD-related complications has not been determined.
胃食管反流病(GERD)的治疗目标是控制症状、治愈受损的食管黏膜并预防并发症。药物治疗在缓解急性症状、促进黏膜愈合以及长期维持病情缓解方面有效。质子泵抑制剂是GERD治疗的主要药物。然而,每日给药的必要性、无法完全缓解症状以及这些药物的成本可能会限制它们在某些患者中的使用,这促使人们考虑其他治疗策略。腹腔镜胃底折叠术可能会使这些患者的症状得到缓解且食管炎愈合,但它的侵入性、成本以及固有的手术风险引发了人们对GERD内镜治疗的兴趣,在过去几年中有几种内镜治疗方法出现。这些干预措施既可以被视为一种替代疗法,也可以被视为“桥梁”疗法,如果内镜手术未能充分缓解症状或症状复发,患者仍可选择使用抑酸药物或胃底折叠术进行治疗。患者的选择对于胃底折叠术以及内镜手术的成功至关重要,理想的候选者是那些内镜检查确诊为GERD、pH监测异常、食管动力检查正常且使用质子泵抑制剂治疗后症状至少有部分缓解的患者。食管裂孔疝并非胃底折叠术的禁忌证,而内镜干预最适合食管裂孔疝长度小于3厘米的患者。内镜手术对GERD食管外表现的长期疗效、成本效益以及影响,以及GERD相关并发症的风险尚未确定。